Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity

[1]  R. Mohan,et al.  Severe lymphopenia during neoadjuvant chemoradiation for esophageal cancer: A propensity matched analysis of the relative risk of proton versus photon-based radiation therapy. , 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[2]  MatsumotoShingo,et al.  Radiotherapy Synergizes with the Hypoxia-Activated Prodrug Evofosfamide: In Vitro and In Vivo Studies. , 2018 .

[3]  Frank Verhaegen,et al.  ESTRO ACROP: Technology for precision small animal radiotherapy research: Optimal use and challenges. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[4]  R. Anderson,et al.  Antagonism in effectiveness of evofosfamide and doxorubicin through intermolecular electron transfer , 2017, Free radical biology & medicine.

[5]  P. Lambin,et al.  Hypoxia and hypoxia response-associated molecular markers in esophageal cancer: A systematic review. , 2017, Methods.

[6]  C. Simone.  Thoracic Radiation Normal Tissue Injury. , 2017, Seminars in radiation oncology.

[7]  L. Dubois,et al.  Nintedanib reduces radiation-induced microscopic lung fibrosis but this cannot be monitored by CT imaging: A preclinical study with a high precision image-guided irradiator. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[8]  Robin L. Jones,et al.  Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial. , 2017, The Lancet. Oncology.

[9]  Steven H. Lin,et al.  Recent advances in intensity modulated radiotherapy and proton therapy for esophageal cancer , 2017, Expert review of anticancer therapy.

[10]  T. Muanza,et al.  Radiation-Induced Oral Mucositis , 2017, Front. Oncol..

[11]  P. Lambin,et al.  A novel concept for tumour targeting with radiation: Inverse dose-painting or targeting the "Low Drug Uptake Volume". , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[12]  Uwe Siebert,et al.  Personalized medicine in Europe: not yet personal enough? , 2017, BMC Health Services Research.

[13]  Recinda L. Sherman,et al.  Annual Report to the Nation on the Status of Cancer, 1975–2014, Featuring Survival , 2017, Journal of the National Cancer Institute.

[14]  O. Riesterer,et al.  The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy , 2017, Oncotarget.

[15]  P. Lambin,et al.  A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients , 2016, BMC Cancer.

[16]  M. Konopleva,et al.  Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia , 2016, American journal of hematology.

[17]  V. Ponomarev,et al.  Anticancer efficacy of the hypoxia‐activated prodrug evofosfamide (TH‐302) in osteolytic breast cancer murine models , 2016, Cancer Medicine.

[18]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[19]  E. Steyerberg,et al.  Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. , 2015, The Lancet. Oncology.

[20]  D. Hedley,et al.  Analysis of the intra- and intertumoral heterogeneity of hypoxia in pancreatic cancer patients receiving the nitroimidazole tracer pimonidazole , 2015, British Journal of Cancer.

[21]  A. Windhorst,et al.  Feasibility and repeatability of PET with the hypoxia tracer [(18)F]HX4 in oesophageal and pancreatic cancer. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[22]  J. Kao,et al.  Esophagus and Contralateral Lung-Sparing IMRT for Locally Advanced Lung Cancer in the Community Hospital Setting , 2015, Front. Oncol..

[23]  F. Meng,et al.  Combination treatment with hypoxia-activated prodrug evofosfamide (TH-302) and mTOR inhibitors results in enhanced antitumor efficacy in preclinical renal cell carcinoma models. , 2015, American journal of cancer research.

[24]  M. Borad,et al.  Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  P. Lambin,et al.  TH-302 in Combination with Radiotherapy Enhances the Therapeutic Outcome and Is Associated with Pretreatment [18F]HX4 Hypoxia PET Imaging , 2015, Clinical Cancer Research.

[26]  V. Ponomarev,et al.  Hypoxia-activated pro-drug TH-302 exhibits potent tumor suppressive activity and cooperates with chemotherapy against osteosarcoma. , 2015, Cancer letters.

[27]  Frank Verhaegen,et al.  A longitudinal evaluation of partial lung irradiation in mice by using a dedicated image-guided small animal irradiator. , 2014, International journal of radiation oncology, biology, physics.

[28]  H. Kolb,et al.  The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities. , 2014, Antioxidants & redox signaling.

[29]  I. Tannock,et al.  Activity of the hypoxia‐activated pro‐drug TH‐302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy , 2014, International journal of cancer.

[30]  Sergei A. Vinogradov,et al.  Direct measurement of local oxygen concentration in the bone marrow of live animals , 2014, Nature.

[31]  M. Wetzler,et al.  Activity of the Hypoxia-Activated Prodrug, TH-302, in Preclinical Human Acute Myeloid Leukemia Models , 2013, Clinical Cancer Research.

[32]  C. Hart,et al.  Synergistic Induction of Apoptosis in Multiple Myeloma Cells by Bortezomib and Hypoxia-Activated Prodrug TH-302, In Vivo and In Vitro , 2013, Molecular Cancer Therapeutics.

[33]  F. Sullivan,et al.  Gastrointestinal radiation injury: symptoms, risk factors and mechanisms. , 2013, World journal of gastroenterology.

[34]  R. Gillies,et al.  Imaging biomarkers to monitor response to the hypoxia-activated prodrug TH-302 in the MiaPaCa2 flank xenograft model. , 2012, Magnetic resonance imaging.

[35]  E. Deutsch,et al.  Normal tissues toxicities triggered by combined anti-angiogenic and radiation therapies: hurdles might be ahead , 2012, British Journal of Cancer.

[36]  Damien J. Ferraro,et al.  Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer , 2011, Clinical Cancer Research.

[37]  P. Glazer,et al.  Molecular and Cellular Pharmacology of the Hypoxia-Activated Prodrug TH-302 , 2011, Molecular Cancer Therapeutics.

[38]  K. Ganjoo,et al.  A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma , 2011, Oncology.

[39]  S. McKenna,et al.  Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics , 2011, Autophagy.

[40]  Suzanne F. Jones,et al.  Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies , 2011, Clinical Cancer Research.

[41]  D A Jaffray,et al.  Characterization of image quality and image-guidance performance of a preclinical microirradiator. , 2011, Medical physics.

[42]  J. Overgaard,et al.  Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode , 2010, Acta oncologica.

[43]  Max A. Viergever,et al.  elastix: A Toolbox for Intensity-Based Medical Image Registration , 2010, IEEE Transactions on Medical Imaging.

[44]  M. Boerma,et al.  The Somatostatin Analog SOM230 (Pasireotide) Ameliorates Injury of the Intestinal Mucosa and Increases Survival after Total-Body Irradiation by Inhibiting Exocrine Pancreatic Secretion , 2009, Radiation research.

[45]  M. Boerma,et al.  γ-Tocotrienol Ameliorates Intestinal Radiation Injury and Reduces Vascular Oxidative Stress after Total-Body Irradiation by an HMG-CoA Reductase-Dependent Mechanism , 2009, Radiation research.

[46]  P. Lambin,et al.  Inhibition of 4E-BP1 sensitizes U87 glioblastoma xenograft tumors to irradiation by decreasing hypoxia tolerance. , 2009, International journal of radiation oncology, biology, physics.

[47]  G. Gardani,et al.  Radiotherapy-induced lymphocytopenia: changes in total lymphocyte count and in lymphocyte subpopulations under pelvic irradiation in gynecologic neoplasms. , 2005, Journal of biological regulators and homeostatic agents.

[48]  P. Lambin,et al.  Citrulline: a physiologic marker enabling quantitation and monitoring of epithelial radiation-induced small bowel damage. , 2003, International journal of radiation oncology, biology, physics.